4//SEC Filing
ARIAD PHARMACEUTICALS INC 4
Accession 0000884731-17-000051
CIK 0000884731operating
Filed
Feb 15, 7:00 PM ET
Accepted
Feb 16, 2:15 PM ET
Size
309.4 KB
Accession
0000884731-17-000051
Insider Transaction Report
Form 4
Panayiotopoulos Paris
DirectorPresident and CEO
Transactions
- Disposition to Issuer
Common Stock
2017-02-16−159,378→ 0 total - Disposition to Issuer
Employee Stock Option (Right to Buy)
2017-02-16−1,500,000→ 0 totalExercise: $5.34→ Common Stock (1,500,000 underlying) - Disposition to Issuer
Restricted Stock Units
2017-02-16−66,800→ 0 totalExercise: $0.00→ Common Stock (66,800 underlying)
Footnotes (3)
- [F1]Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash.
- [F2]Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.
- [F3]Each restricted stock unit ("RSU") represents a right to receive one Share. Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes.
Issuer
ARIAD PHARMACEUTICALS INC
CIK 0000884731
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000884731
Filing Metadata
- Form type
- 4
- Filed
- Feb 15, 7:00 PM ET
- Accepted
- Feb 16, 2:15 PM ET
- Size
- 309.4 KB